Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of obinutuzumab in active lupus nephritis
jRCT2011210059Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing Obinutuzumab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Complete renal response at Week 76. Started Jun 2022; status: active, not recruiting.
02
Drugs
obinutuzumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2011210059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210059.